Английская Википедия:Abraxis BioScience
Шаблон:Short description Шаблон:Infobox company
Abraxis BioScience was a global biopharmaceutical, and nano-medicine company that developed treatments for critically ill patients. It had over 2000 employees worldwide in 2007.[1] Abraxis's portfolio included the world's first protein-based nanoparticle chemotherapeutic compound, called nab Technology.[2] From this the company developed Abraxane, a treatment for metastatic breast cancer.[3]
In 2010, Abraxis BioScience was acquired by Celgene Corporation.[4]
History
Abraxis was incorporated in 2001 in Los Angeles.[5] It was formerly known as American Pharmaceutical Partners (APP), which as known for its injectable oncology, anti-infective and critical care.[6] Besides cancer treatments, it provided treatment for multiple sclerosis, Alzheimer's, and some cardiovascular diseases.[5] It had manufacturing plants in Melrose Park, Illinois and Phoenix, Arizona.[5] By 2005, Dr. Patrick Soon-Shiong merged American BioScience and the publicly-held APP, naming it Abraxis BioScience.[7] Under this new name, seventy-four trials were undertaken to test Abraxane against various cancer targets.[7] The drug, which was approved by the FDA in 2005, was the subject of a litigation (Elan Pharma v. Abraxis BioScience) for patent infringement.[8] In 2008, Abraxis was ordered to pay $55.2 million to Elan.[8]
In August 2007, Abraxis announced it would again undergo a restructuring to separate its "hospital-based products business" from its "proprietary products business" into two public companies; this would involve the merging of Abraxis Oncology and Abraxis Research sub-units to form a new Abraxis Bioscience (Abraxis Bioscience, Inc., Шаблон:NASDAQ), and the spinoff of Abraxis Pharmaceutical Products (APP, Inc., Шаблон:NASDAQ).[9] This reorganization was completed in November 2007.[10] During the reorganization, the new Abraxis Bioscience was known briefly as New Abraxis.[10]
In 2010, Abraxis BioScience was acquired by Celgene Corporation.[4] Per Celgene's website, as of at least 2016 Abraxis no longer exists as a named division within Celgene.Шаблон:Citation needed
References
External links
- ↑ BioPortfolio, 2007, "InDepth Summary", 10/11/2009Шаблон:Dead link
- ↑ Abraxis BioScience, 2008, "Nab Technology", 10/11/2009
- ↑ Hoovers. Шаблон:Webarchive
- ↑ 4,0 4,1 Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.
- ↑ 5,0 5,1 5,2 Ошибка цитирования Неверный тег
<ref>; для сносокbbergне указан текст - ↑ Шаблон:Cite book
- ↑ 7,0 7,1 Шаблон:Cite book
- ↑ 8,0 8,1 Шаблон:Cite book
- ↑ Шаблон:Cite news
- ↑ 10,0 10,1 Шаблон:Cite report
- Английская Википедия
- Defunct biotechnology companies of the United States
- Defunct pharmaceutical companies of the United States
- Biotechnology companies established in 2001
- Pharmaceutical companies established in 2001
- 2001 establishments in California
- Biotechnology companies disestablished in 2010
- Pharmaceutical companies disestablished in 2010
- 2010 disestablishments in California
- Health care companies based in California
- 2010 mergers and acquisitions
- Defunct technology companies based in New York City
- American companies disestablished in 2010
- American companies established in 2001
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
- Страницы с ошибками в примечаниях
